Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 15;11(6):e220101.
doi: 10.1530/EC-22-0101.

Analysis of a pitfall in congenital adrenal hyperplasia newborn screening: evidence of maternal use of corticoids detected on dried blood spot

Muriel Houang  1 , Thao Nguyen-Khoa  2 , Thibaut Eguether  3   4 , Bettina Ribault  3   4 , Séverine Brabant  5 , Michel Polak  2   6 , Irène Netchine  1   3   7 , Antonin Lamazière  3   4
Affiliations

Analysis of a pitfall in congenital adrenal hyperplasia newborn screening: evidence of maternal use of corticoids detected on dried blood spot

Muriel Houang et al. Endocr Connect. .

Abstract

Neonatal screening for congenital adrenal hyperplasia (CAH) faces many specific challenges. It must be done using a performant analytical approach that combines sensitivity and specificity to capture the potential causes of mortality during the first week of life, such as salt wasting and glucocorticoid deficiency. Here, we confirm that maternal inhaled corticosteroid intake during pregnancy is a possible cause of missed CAH diagnosis. Thanks to liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) analysis, we were able to quantify endogenous steroid metabolites and also detect the presence of exogenous steroids in the dried blood spot of a newborn. Adding LC-MS/MS analysis as second-tier test, especially one that includes both 17-hydroxyprogesterone and 21-deoxycortisol measurements, would probably improve CAH diagnosis. In familial neonatal screening one could also look for maternal corticosteroid therapies that are hidden to prevent false-negative tests.

Keywords: 17-hydroxyprogesterone; CAH; dried blood spot; glucocorticoid treatment; newborn screening.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Identification of a peak corresponding to maternal intake of triamcinolone in the index case newborn dried blood spot compared to control (CTRL) and to CAH patient newborn blood spots (MRM fragmentation transition m/z 435 → 415).
See this image and copyright information in PMC

References

    1. Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocrine Reviews 20113281–151. ( 10.1210/er.2010-0013) - DOI - PMC - PubMed
    1. Dhondt JL, Dorche C, Farriaux JP, Courte C. Neonatal screening for congenital adrenal hyperplasia: a pilot study in France. Journal of Inherited Metabolic Disease 19869 (Supplement 1) 147–151. ( 10.1007/BF01800869) - DOI - PubMed
    1. Hannon WH.Clinical, Laboratory Standards I. Blood Collection on Filter Paper for Newborn Screening Programs. Wayne, PA, USA: Approved Standard. Clinical and Laboratory Standards; Institute, 2013.
    1. Lacey JM, Minutti CZ, Magera MJ, Tauscher AL, Casetta B, McCann M, Lymp J, Hahn SH, Rinaldo P, Matern D. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. Clinical Chemistry 200450621–625. ( 10.1373/clinchem.2003.027193) - DOI - PubMed
    1. Janzen N, Peter M, Sander S, Steuerwald U, Terhardt M, Holtkamp U, Sander J. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry. Journal of Clinical Endocrinology and Metabolism 2007922581–2589. ( 10.1210/jc.2006-2890) - DOI - PubMed

LinkOut - more resources